RBX
Genentech sold GDC0084 with a licence agreement in 2016
Genentech has not had to worry about ongoing expenditure for2016, 2017,2018,2019 etc
Genentech has received an upfront payment of $5m plus other entitlements - milestone payments as per licence agreement
Genentech does not need worry about upwards of $20m for phase 11b trial and imo will receive a milestone payment if phase 11b commences
Genentech does not need to hit the market for capital for GDC0084
DYOR all above fair and realistic debating points
- Forums
- ASX - By Stock
- KZA
- Value of Cantrixil
Value of Cantrixil, page-9
-
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online